Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Optic, Atrophy, Hereditary, Leber

Interventions

BIOLOGICAL: GS010
DEVICE: Sham Intravitreal Injection

Sponsor

GenSight Biologics